Related Experiment Videos
Separating graft-versus-tumor from graft-versus-host reactions
A B T Fassas1, C Morris, A Badros
1Myeloma and Transplantation Research Center, University of Arkansas for Medical Sciences, Little Rock 72205, USA. fassasathanasios@uams.edu
Leukemia & Lymphoma
|August 3, 2002
Summary
Graft-versus-host disease limits allogeneic stem cell transplants for blood cancers. Separating graft-versus-host disease from the beneficial graft-versus-tumor effect requires understanding T-cell responses.
Area of Science:
- Hematology
- Immunology
- Oncology
Background:
- Allogeneic stem cell transplantation (SCT) offers therapeutic potential for hematologic malignancies via graft-versus-tumor (GVT) effect.
- Graft-versus-host disease (GVHD) significantly compromises the efficacy of allogeneic SCT.
- Current strategies using broad immunosuppression to mitigate GVHD increase risks of infection and malignancy relapse.
Purpose of the Study:
- To critically review clinical attempts to separate the beneficial GVT effect from detrimental GVHD.
- To highlight the challenges in abrogating GVHD while preserving GVT responses in allogeneic SCT.
Main Methods:
- Critical overview of published clinical experiences and strategies.
- Analysis of the immunological basis for GVT and GVHD.
Main Results:
- Limited success has been achieved in clinically separating GVT and GVHD.
- The effector cells and specific antigenic stimuli driving these responses remain largely unidentified.
Conclusions:
- A deeper understanding of the antigenic triggers and molecular pathways of T-cell-mediated GVT and GVHD is crucial.
- Elucidating these mechanisms is essential for developing targeted strategies to prevent GVHD while maintaining the anti-leukemic GVT effect in allogeneic SCT.